AOD9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
microfilament A long, thin, flexible, rod-like structure composed of polymeric strands of proteins, usually actins, that occurs in abundance in the cytoplasm of eukaryotic cells, forming part of the cytoskeleton. Microfilaments comprise the cell's structural framework. They are modified by and interact with numerous other cytoplasmic proteins, playing important roles in cell stability, motility, contractility, and facilitating changes in cell shape, as well as in cytokinesis.
=== Professional ski wax technicians === Compared to the general public exposed to contaminated drinking water, professional ski wax technicians are more strongly exposed to PFAS (PFOA, PFNA, PFDA, PFHpA, PFDoDA) from the glide wax used to coat the bottom of skis to reduce the friction between the skis and snow. During the coating process, the wax is heated, which releases fumes and airborne particles. Compared to all other reported occupational and residential exposures, ski waxing had the highest total PFAS air concentrations.
=== 23 April === Russia claimed to have captured the village of Ocheretyne, Donetsk Oblast, which was attributed to a rotational error by Ukrainian military commanders that left the sector mostly undefended and led to Russian forces advancing by five kilometers. The Ukrainian foreign ministry announced that it would suspend consular services to overseas Ukrainian men who were eligible for military service until 18 May, with the exception of those returning to Ukraine. The SBU arrested a resident of Kharkiv on suspicion of spying for Russia. UK Prime Minister Rishi Sunak announced a new military aid package for Ukraine that included 400 vehicles, 1,600 weapons and four million rounds of ammunition, along with £500 million in funding. The US Senate passed the bill authorising financial aid for Ukraine. The bill must now be signed into law by President Joe Biden.
== External links == http://www.asap.unimelb.edu.au/asap_inf.htm – Australian Science Archives Project From http://www.asap.unimelb.edu.au/bsparcs/aasmemoirs AAS Biographical Memoirs (1966–1996) From http://www.sciencearchive.org.au "Fellows elected in 2005". Australian Academy of Science. Archived from the original on 25 March 2016. "Fellows elected in 2006". Australian Academy of Science. Archived from the original on 23 March 2016. "Fellows elected in 2007". Australian Academy of Science. Archived from the original on 1 April 2016. "Fellows elected in 2008". Australian Academy of Science. Archived from the original on 23 March 2016. "Fellows elected in 2009". Australian Academy of Science. Archived from the original on 24 September 2015. "Fellows elected in 2010". Australian Academy of Science. Archived from the original on 3 April 2016. "Fellows elected in 2011". Australian Academy of Science. Archived from the original on 24 September 2015. "Fellows elected in 2012". Australian Academy of Science.{{cite web}}: CS1 maint: deprecated archival service (link) "Fellows elected in 2013". Australian Academy of Science. Archived from the original on 25 March 2016. From https://www.science.org.au "Fellows elected in 2010". Australian Academy of Science. "Fellows elected in 2011". Australian Academy of Science. "Fellows elected in 2012". Australian Academy of Science. "Fellows elected in 2013". Australian Academy of Science. "Fellows elected in 2014". Australian Academy of Science. "Fellows elected in 2015". Australian Academy of Science. "Fellows elected in 2016".
Sources: en.wikipedia.org
=== Discovery and development === The patent for Vicoprofen was filed in December 1984, and US patent number 4,587,252 was granted in May 1986. Although ibuprofen and hydrocodone were already available on the market at this time, the fact that they had never been supplied together in a single formulation required approval from the FDA as if it were a new drug. Knoll filed an investigational new drug application on 30 December 1986. A new drug application was later filed by Knoll on 25 April 1996, and received final approval from the FDA on 23 September 1997. Vicoprofen tablets were initially formulated and packaged by Knoll, with ibuprofen supplied by Albemarle Corporation and hydrocodone supplied by Mallinckrodt Pharmaceuticals. The validity of Knoll's patent on Vicoprofen has been challenged in federal court. In September 2002, the US District Court for the Northern District of Illinois granted a motion of invalidity filed by Teva Pharmaceuticals against Knoll's patent on Vicoprofen, ruling the patent was invalid as obvious. This ruling paved the way for Teva's abbreviated new drug application to be approved by the FDA which would allow them to manufacture and market their own generic. Knoll appealed the decision. In April 2003, Teva announced that its abbreviated new drug application had been approved by the FDA, and its generic would begin shipping immediately.
The left paratracheal stripe is more variable and only seen in 25% of normal patients on posteroanterior views. Localization of lesions or inflammatory and infectious processes can be difficult to discern on chest radiograph, but can be inferred by silhouetting and the hilum overlay sign with adjacent structures. If either hemidiaphragm is blurred, for example, this suggests the lesion to be from the corresponding lower lobe. If the right heart border is blurred, than the pathology is likely in the right middle lobe, though a cavum deformity can also blur the right heard border due to indentation of the adjacent sternum. If the left heart border is blurred, this implies a process at the lingula.
There are also several passages with chains that begin with the six sense spheres (ayatana). They can be found in SN 12. 24, SA 343, SA 352-354, SN 12. 13-14 and SN 12. 71-81. Another one of these is found in SN 35.106, which is termed the "branched version" by Bucknell because it branches off into six classes of consciousness:Eye consciousness arises dependent on the eye and sights. The meeting of the three is contact. Contact is a condition for feeling. Feeling is a condition for craving. This is the origin of suffering … [the same formula is repeated with the other six sense bases and six consciousnesses, that is, ear, nose, tongue, body, and mind]Other depictions of the chain at SN 12.52 and its parallel at SA 286, begin with seeing the assada (taste; enjoyment; satisfaction) which leads to craving and the rest of the list of nidanas. Meanwhile, in SN 12.62 and SA 290, dependent origination is depicted with just two nidanas, contact (phassa) and feeling (vedana). SN 12.62 says that when one becomes disenchanted with contact and feeling, desire fades away.
Sources: en.wikipedia.org
In October 2006, researchers announced that three atoms of oganesson (element 118) had been identified at Joint Institute for Nuclear Research in Dubna, Russia, from bombarding 249Cf with calcium-48, making it the heaviest element ever made. The target contained about 10 mg of 249Cf deposited on a titanium foil of 32 cm2 area. Californium has also been used to produce other transuranic elements; for example, lawrencium was first synthesized in 1961 by bombarding californium with boron nuclei.
=== Quantum tunneling === Quantum mechanics, however, allows the alpha particle to escape via quantum tunneling. The quantum tunneling theory of alpha decay, independently developed by George Gamow and by Ronald Wilfred Gurney and Edward Condon in 1928, was hailed as a very striking confirmation of quantum theory. Essentially, the alpha particle escapes from the nucleus not by acquiring enough energy to pass over the wall confining it, but by tunneling through the wall. Gurney and Condon made the following observation in their paper on it:
=== 3-2-1 Backup Rule === The backup data needs to be stored, requiring a backup rotation scheme, which is a system of backing up data to computer media that limits the number of backups of different dates retained separately, by appropriate re-use of the data storage media by overwriting of backups no longer needed. The scheme determines how and when each piece of removable storage is used for a backup operation and how long it is retained once it has backup data stored on it. The 3-2-1 rule can aid in the backup process. It states that there should be at least 3 copies of the data, stored on 2 different types of storage media, and one copy should be kept offsite, in a remote location (this can include cloud storage). 2 or more different media should be used to eliminate data loss due to similar reasons (for example, optical discs may tolerate being underwater while LTO tapes may not, and SSDs cannot fail due to head crashes or damaged spindle motors since they do not have any moving parts, unlike hard drives). An offsite copy protects against fire, theft of physical media (such as tapes or discs) and natural disasters like floods and earthquakes. Physically protected hard drives are an alternative to an offsite copy, but they have limitations like only being able to resist fire for a limited period of time, so an offsite copy still remains as the ideal choice. Because there is no perfect storage, many backup experts recommend maintaining a second copy on a local physical device, even if the data is also backed up offsite.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.